Skip Navigation


Annals of Oncology Advance Access originally published online on October 24, 2007
Annals of Oncology 2007 18(12):2037-2040; doi:10.1093/annonc/mdm382
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/2037    most recent
mdm382v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bacci, G.
Right arrow Articles by Picci, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacci, G.
Right arrow Articles by Picci, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

sarcomas

Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment

G. Bacci1,*, A. Balladelli2, C. Forni1, S. Ferrari1, A. Longhi1, M. S. Benassi4, A. Briccoli3, M. Serra4 and P. Picci4

1 Section of Chemotherapy
2 Department of Orthopaedic Surgery
3 Section of General Surgery
4 Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

* Correspondence to: Dr G. Bacci, Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy. Tel: +39-051-6366829; Fax: +39-051-6366277; E-mail: gaetano.bacci{at}ior.it

Background: In 326 patients with Ewing's sarcoma family tumor (ESFT) and 628 extremity osteosarcoma (OS) treated with adjuvant and neo-adjuvant chemotherapy and event-free survivors 5 years from the beginning of treatment we evaluated outcome in the following years. Post 5-year follow-up for these patients was 9.7 years (5.5–29 years).

Patients and methods: Adverse events observed after 5-year follow-up were 73 (7.6%): 38 late relapses, nine leukemia, 14 second solid tumor, seven radioinduced sarcoma, three severe adriamycin-related cardiomyopathy, one suicide and one death by car crash.

Results: Of the patients who developed late events, 16 (22.5%) are alive and event free after 8 years from the last treatment (2–22 years).

Conclusion: We conclude that the high rate of late adverse events after 5 years in patients with OS and ESFT is noteworthy and indicates that these patients should be followed for >5 years.

Key words: adriamycin cardiopathy, Ewing's sarcoma, late events, osteosarcoma, radioinduced sarcoma, second malignancy

Received for publication March 27, 2007. Revision received June 14, 2007. Accepted for publication July 7, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.